<DOC>
	<DOCNO>NCT00114556</DOCNO>
	<brief_summary>Following liver transplantation , rapid bone loss occur , particularly within first 6 month post-transplant . This may associate fracture , notable vertebral . The ability ass osteoporosis therapy system may provide useful information osteoporosis management general . Hypotheses : 1 . That treatment bisphosphonate , zoledronate , time liver transplantation 1 month post-transplantation prevent early transplant-related bone loss ( measure bone densitometry biochemical bone marker 3 month ) see patient treat bisphosphonate 2 . That continue treatment zoledronate 3 monthly interval total duration 12 month result improvement bone density beyond see 3 month 3 . That calcium vitamin D ( vit D ) supplementation liver transplant patient prevent marked bone loss follow transplantation .</brief_summary>
	<brief_title>The Effect Zoledronic Acid Bone Density Liver Transplant Patients</brief_title>
	<detailed_description>This study prospective , randomised , double-blind , placebo-controlled clinical trial liver transplant patient compare therapy bisphosphonate , zoledronate , patient receive bisphosphonate therapy . All group receive calcium vit D supplementation time patient list transplantation 12 month post-transplantation . Recruited subject 17 year old ( ie adult term consent requirement ) . The study group comprise : Group 1 : Zoledronate plus calcium vit D supplementation Zoledronate 4 mg administer intravenous infusion ( detail ) baseline ( within 72 h liver transplantation ) , follow zoledronate 4 mg infuse outlined 1 , 3 , 6 9 month post-transplantation PLUS calcium 600mg daily ( Caltrate , one tablet ) ergocalciferol 1000 IU daily ( Ostelin , one capsule ) 12 month post-transplantation . Group 2 : Placebo plus calcium vit D supplementation Placebo consist 50 ml N/Saline infuse 15 minute zoledronate regime PLUS calcium 600mg daily ( Caltrate , one tablet ) ergocalciferol 1000 IU daily ( Ostelin , one capsule ) . Patients low vitamin D level ( &lt; 60 nmol/L ) parathyroid hormone ( Pth ) level normal &gt; 6.5 receive ergocalciferol 5000 U daily . Zoledronate/Placebo Infusion regime Zoledronate 4 mg infuse 100 ml N/Saline 15 minute patient creatinine level &lt; 1.5 time upper limit normal range ( i.e &lt; 165 Âµmol/L ) . Patients renal impairment indicate serum creatinine level &gt; 1.5 x ULN discuss individual basis Medical Adviser Novartis . If zoledronate give , extend infusion time may use . Renal toxicity report rapid infusion ( 5 min ) 8 mg zoledronate patient pre-existing renal failure . Further pharmacokinetic study patient renal failure undertaken Novartis clarify area . Zoledronate infusion freshly prepared administer without delay . The Hospital Pharmacy responsible provide infusion ( zoledronate reconstitute N/Saline N/Saline alone ) , appropriately mask , Groups 1 2 . Primary Outcome Measures : 1 ) Bone Density 3 month post-transplantation Maximal loss bone follow transplantation see 3 month . Earlier data bone loss liver transplant patient RPAH unit demonstrate average 24 % bone loss 3 month post-transplantation . Prevention effect provide precise early measurement effect zoledronate transplant-related bone loss . Bone density hip , spine , total body measure dual xray absorptiometry ( DEXA ) baseline ( 6 month prior liver transplantation ) , 3 , 6 12 month follow liver transplantation . Secondary Outcome Measures : 1 . Bone Density 6 12 month post-transplantation The BMD assessments 6 12 month assess change bone density treat control group beyond assessed 3 month . 2 . Biochemical Markers Bone Metabolism Biochemical marker bone formation ( osteocalcin total bone specific alkaline phosphatase ) bone resorption ( urinary collagen cross-link , N-teleopeptide deoxypyridinoline , well serum cross-link , C-teleopeptide ) assay serum/urine collect baseline , 1 , 3 , 6 , 9 12 month follow liver transplantation . 3 . Fracture Events Fracture incidence RPAH patient previously report 17 % first 6 month post-transplantation . The fracture rate probably low due improvement immunosuppressive therapy . It anticipate study sufficient power detect significant reduction fracture however fracture event record , include reduction height vertebral body baseline 12 month post-transplantation .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Greater 17 year age Concurrent treatment , within past 12 month , drug know affect bone metabolism Hypocalcemia Renal impairment ( creatinine &gt; 1.5x ULN )</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2004</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>liver transplantation</keyword>
</DOC>